An Examination of Concomitant Non-Medical Use of Gabapentin and Opioids.
加巴喷丁和阿片类药物同时非医疗用途的检查。
基本信息
- 批准号:10707282
- 负责人:
- 金额:$ 13.79万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-30 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAnxietyBehavioralBlack raceBuprenorphineCase StudyCause of DeathCharacteristicsChemosensitizationClassificationClientCommunitiesDangerousnessDataDecision ModelingDevelopmentDoseDrug Metabolic DetoxicationEcologyEpidemiologyEpilepsyEthnographyFundingGoalsHealth PersonnelHispanicHydrocodoneIndividualInterventionInterviewLabelLawsMedical ExaminersMethadoneMethodologyMotivationNational Institute of Drug AbuseNeuralgiaNeurologyOpioidOxycodonePain managementParticipantPatientsPharmaceutical PreparationsPlacebosPopulationPrevention strategyPrimary Health CareProbabilityProviderPsychiatryPublic HealthPublic PolicyRecording of previous eventsRelapseReport (document)ReportingResearchResearch PersonnelRisk FactorsRouteSamplingScheduleSocial EnvironmentStrategic PlanningSubstance Use DisorderSurveysSymptomsTestingTherapeuticTimeUnited States Food and Drug AdministrationUrineVentilatory DepressionWithdrawal SymptomWomanWorkanalogbehavior influencedesignethnic differencefentanyl analoggabapentingamma-Aminobutyric Acidgender differencehealth knowledgeillicit opioidinnovationmedication-assisted treatmentmennonmedical useopioid agonist therapyopioid epidemicopioid overdoseopioid use disorderopioid useropioid withdrawalprescription monitoring programprescription opioidprotective factorspsychosocialracial differencereduce symptomssocialsocial culturesubstance use treatmenttheoriestreatment center
项目摘要
Project Summary/Abstract
Gabapentin is widely prescribed in neurology, psychiatry, and primary healthcare for the treatment of epilepsy
and neuralgia, as well as off- label during treatment for opioid use disorder (OUD) to mitigate withdrawal
symptoms, manage pain, and address patient anxiety. From 2002-2015, prescriptions for gabapentin tripled,
and gabapentin-involved opioid overdoses have also increased in recent years. As a result, starting in 2017,
multiple states reclassified gabapentin to Schedule V under state-controlled substances laws. In 2019, the
Food and Drug Administration required labeling changes for gabapentin that included a warning of potential
respiratory depression when used with opioids medications. Limited reports document non-medical use (NMU)
of gabapentin, especially among opioid users and individuals receiving medication assisted treatment (MAT)
for OUD. Gabapentin is non-medically used to potentiate the euphoric effects of opioids, including MAT
medications buprenorphine and methadone, as well as to self-treat OUD symptoms. Aside from these brief
reports, systematic studies examining the concomitant NMU of gabapentin and opioids are lacking. At the
same time, research documents the therapeutic benefits of administering gabapentin to individuals in treatment
for substance use disorder. Studies have shown that individuals receiving daily doses of gabapentin reported
decreased symptoms of withdrawal and gabapentin works well in combination with methadone for opioid
detoxification. Given the growing reports of NMU of gabapentin, especially NMU co-occurring with opioids and
MAT; the accepted use of prescribed gabapentin among treatment clients; and the dearth of systematic data
examining the concomitant NMU of gabapentin and opioids, the proposed exploratory R21 study seeks to
examine this phenomenon. The study will utilize a social ecology theory-driven design to investigate
motivations for concomitant NMU, gender and racial/ethnic differences, and histories of MAT and prescribed
gabapentin. The following specific aims will be accomplished: 1) Assess demographic, sociocultural, and
psychosocial characteristics across three social ecological domains (intrapersonal, interpersonal, and
community) which influence concomitant NMU of gabapentin/opioids; and routes of administration, modes of
acquisition, and consequences (n=150); 2) Construct and ethnographic decision model (EDM) of the decision
to initiate concomitant NMU of gabapentin/opioids (n=60); and 3) Examine NMU of gabapentin in combination
with MAT, including motivations, effects, and consequences (n=30). The sample will be collected among
individuals entering treatment for OUD and will include approximately equal numbers of men and women, as
well as, and Black, Hispanic, and white individuals. The study will advance Goal 1 of NIDA’s strategic plan by
identifying environmental, behavioral, and social causes and consequences of concomitant NMU of gabapentin
and opioids and it will be informative for OUD treatment providers and prescribers and aid in the development
of prevention and intervention strategies. This exploratory study is innovative in its use of EDM methodology.
项目总结/摘要
加巴喷丁被广泛用于神经病学、精神病学和初级卫生保健领域,用于治疗癫痫
和神经痛,以及阿片类药物使用障碍(OUD)治疗期间的标签外使用,以减轻戒断
症状,管理疼痛,并解决患者的焦虑。从2002年到2015年,加巴喷丁的处方增加了两倍,
近年来,加巴喷丁涉及的阿片类药物过量也有所增加。因此,从2017年开始,
多个州将加巴喷丁重新归类为国家管制物质法下的附表V。2019年
美国食品和药物管理局要求加巴喷丁的标签变更,其中包括潜在的警告
与阿片类药物一起使用时的呼吸抑制。有限报告记录非医疗用途(NMU)
加巴喷丁,特别是在阿片类药物使用者和接受药物辅助治疗(MAT)的个人中
对于OUD。加巴喷丁非医学用途,用于增强阿片类药物(包括MAT)的欣快感
药物丁丙诺啡和美沙酮,以及自我治疗OUD症状。除了这些简短的
报告,缺乏检查加巴喷丁和阿片类药物的伴随NMU的系统研究。在
与此同时,研究记录了加巴喷丁对治疗中的个体的治疗益处,
药物使用障碍研究表明,接受每日剂量加巴喷丁的人报告说,
减少戒断症状,加巴喷丁与美沙酮联合治疗阿片类药物效果良好
解毒鉴于加巴喷丁NMU的报告越来越多,特别是NMU与阿片类药物同时发生,
MAT;治疗客户中接受处方加巴喷丁的使用;以及缺乏系统数据
检查加巴喷丁和阿片类药物的伴随NMU,拟议的探索性R21研究旨在
研究这一现象。本研究将以社会生态学理论为主导设计,
伴随NMU的动机、性别和种族/民族差异以及MAT和处方药的历史
加巴喷丁将实现以下具体目标:(1)评估人口、社会文化和
三个社会生态领域的心理社会特征(自我、人际和
影响加巴喷丁/阿片类药物的伴随NMU;以及给药途径、
获得和后果(n = 150); 2)决策的结构和民族志决策模型(EDM)
开始加巴喷丁/阿片类药物的伴随NMU(n = 60);和3)检查加巴喷丁与阿片类药物的组合的NMU
MAT,包括动机,效果和后果(n = 30)。样本将在以下地点收集:
进入OUD治疗的个人,将包括大约相同数量的男性和女性,
以及黑人、西班牙裔和白色人。该研究将通过以下方式推进NIDA战略计划的目标1:
确定加巴喷丁的伴随NMU的环境、行为和社会原因和后果
和阿片类药物,它将为OUD治疗提供者和处方者提供信息,
预防和干预战略。这项探索性的研究是创新的,在其使用EDM方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mance E. Buttram其他文献
Health and social factors associated with alternate routes of administration of prescription opioids among young adult multidrug users
- DOI:
10.1016/j.drugalcdep.2014.09.108 - 发表时间:
2015-01-01 - 期刊:
- 影响因子:
- 作者:
Mance E. Buttram;Steven P. Kurtz - 通讯作者:
Steven P. Kurtz
Understanding motivations and use typologies of gabapentin with opioid agonist medications.
了解加巴喷丁与阿片类激动剂药物的动机和使用类型。
- DOI:
10.1016/j.drugalcdep.2022.109713 - 发表时间:
2022 - 期刊:
- 影响因子:4.2
- 作者:
Matthew S. Ellis;Rida Qureshi;Mance E. Buttram - 通讯作者:
Mance E. Buttram
Trends in prescription opioid misuse among young adult multidrug users in Miami, 2006–2014
- DOI:
10.1016/j.drugalcdep.2015.07.1009 - 发表时间:
2015-11-01 - 期刊:
- 影响因子:
- 作者:
Mance E. Buttram;Steven P. Kurtz - 通讯作者:
Steven P. Kurtz
Benzodiazepine dependence among young adults in the club scene: Data from a second cohort
- DOI:
10.1016/j.drugalcdep.2016.08.314 - 发表时间:
2017-02-01 - 期刊:
- 影响因子:
- 作者:
Steven P. Kurtz;Mance E. Buttram;Maria Pagano - 通讯作者:
Maria Pagano
Associations of Transactional Sex and Sexually Transmitted Infections Among Treatment-Seeking Individuals With Opioid Use Disorder.
寻求治疗的阿片类药物使用障碍患者中性交易与性传播感染的关联。
- DOI:
10.1016/j.amepre.2022.07.011 - 发表时间:
2022 - 期刊:
- 影响因子:5.5
- 作者:
Matthew S. Ellis;Zachary A. Kasper;B. Takenaka;Mance E. Buttram;E. Shacham - 通讯作者:
E. Shacham
Mance E. Buttram的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mance E. Buttram', 18)}}的其他基金
An Examination of Concomitant Non-Medical Use of Gabapentin and Opioids.
加巴喷丁和阿片类药物同时非医疗用途的检查。
- 批准号:
10510127 - 财政年份:2022
- 资助金额:
$ 13.79万 - 项目类别:
相似海外基金
A Randomized Controlled Trial of Cognitive Behavioral Therapy via Videoconference for Anxiety in Children and Adolescents
通过视频会议进行认知行为疗法治疗儿童和青少年焦虑的随机对照试验
- 批准号:
23K02949 - 财政年份:2023
- 资助金额:
$ 13.79万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Behavioral telehealth in low-resource primary care settings for anxiety and depression in youth: A randomized effectiveness-implementation study
资源匮乏的初级保健机构中针对青少年焦虑和抑郁的行为远程医疗:一项随机有效性实施研究
- 批准号:
10731716 - 财政年份:2023
- 资助金额:
$ 13.79万 - 项目类别:
Evaluation of the effectiveness and implementation of online group cognitive behavioral therapy for perinatal women with anxiety disorders.
评估在线团体认知行为治疗对患有焦虑症的围产期妇女的有效性和实施情况。
- 批准号:
22KJ3164 - 财政年份:2023
- 资助金额:
$ 13.79万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Adaptation and implementation of a behavioral mHealth intervention to reduce anxiety and depression and end the HIV epidemic in the rural South
适应和实施行为移动健康干预措施,以减少焦虑和抑郁并结束南方农村地区的艾滋病毒流行
- 批准号:
10619925 - 财政年份:2022
- 资助金额:
$ 13.79万 - 项目类别:
Augmenting the Efficacy of Benzodiazepine Taper with Telehealth-Delivered Cognitive Behavioral Therapy for Anxiety Disorders in Patients Using Prescription Opioids
通过远程医疗提供的认知行为疗法来增强苯二氮卓类药物逐渐减少的疗效,以治疗使用处方阿片类药物的焦虑症患者
- 批准号:
10705005 - 财政年份:2022
- 资助金额:
$ 13.79万 - 项目类别:
Development of an Individualized Cognitive Behavioral Therapy Program for Depression and Anxiety in Older Adults
开发针对老年人抑郁和焦虑的个体化认知行为治疗方案
- 批准号:
22K03175 - 财政年份:2022
- 资助金额:
$ 13.79万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Augmenting the Efficacy of Benzodiazepine Taper with Telehealth-Delivered Cognitive Behavioral Therapy for Anxiety Disorders in Patients Using Prescription Opioids
通过远程医疗提供的认知行为疗法来增强苯二氮卓类药物逐渐减少的疗效,以治疗使用处方阿片类药物的焦虑症患者
- 批准号:
10355810 - 财政年份:2022
- 资助金额:
$ 13.79万 - 项目类别:
Feasibility, Preliminary Effectiveness, and Sustainability of a Cognitive-Behavioral Therapy Program Tailored for Youth with Autism and Anxiety Treated in Real-World Community-Based Clinics
为患有自闭症和焦虑症的青少年量身定制的认知行为治疗计划的可行性、初步有效性和可持续性,并在现实世界的社区诊所进行治疗
- 批准号:
10542409 - 财政年份:2022
- 资助金额:
$ 13.79万 - 项目类别:
An Empirical Study of Cognitive Behavioral Therapy Approaching Anxiety and Related Autism Spectrum Disorder Traits
认知行为疗法治疗焦虑及相关自闭症谱系障碍特征的实证研究
- 批准号:
22H01089 - 财政年份:2022
- 资助金额:
$ 13.79万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Feasibility, Preliminary Effectiveness, and Sustainability of a Cognitive-Behavioral Therapy Program Tailored for Youth with Autism and Anxiety Treated in Real-World Community-Based Clinics
为患有自闭症和焦虑症的青少年量身定制的认知行为治疗计划的可行性、初步有效性和可持续性,并在现实世界的社区诊所进行治疗
- 批准号:
10355838 - 财政年份:2022
- 资助金额:
$ 13.79万 - 项目类别:














{{item.name}}会员




